New England Journal of Medicine· 2016Q1· Clinical trial

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz et al.

6,673citations
Q1SCImago
2016year

Short summary

Once-daily oral semaglutide demonstrated non-inferiority to placebo in reducing major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine